Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
5-Amino-1MQ vs Mazdutide
An educational, source-based comparison of 5-Amino-1MQ and Mazdutide — how each peptide works, what it's researched for, and what to know before going deeper.
Not a peptide but commonly grouped in peptide research. A selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Inhibition increases SAM and NAD+ availability, increasing adipocyte energy expenditure in animal models.
- Diet-induced obesity (rodent)
- White adipose tissue energy expenditure
- Age-related muscle function
- • Investigational; no human clinical trials yet.
- • Not FDA-approved.
A dual agonist of GLP-1 and glucagon receptors, similar to survodutide. The glucagon component increases energy expenditure while GLP-1 suppresses appetite and improves glycemic control.
- Chronic weight management
- Type 2 diabetes
- MASH / NAFLD
- • Investigational; not FDA-approved.
- • Glucagon agonism may affect heart rate and blood pressure.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| 5-Amino-1MQ | NNMT inhibition reduces adiposity in obese mice | Nature Medicine | 2015 | Demonstrated weight loss and improved metabolic profile via NNMT inhibition. |
| Mazdutide | Mazdutide for obesity: Phase 2 results | The Lancet Diabetes & Endocrinology | 2024 | Achieved ~15% mean weight loss at 48 weeks with manageable side effects. |
Side-effect & safety grid
- Investigational; no human clinical trials yet.
- Not FDA-approved.
- Investigational; not FDA-approved.
- Glucagon agonism may affect heart rate and blood pressure.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
5-Amino-1MQ vs Mazdutide — Key differences
- Class: 5-Amino-1MQ is classified as Metabolic · Small Molecule, while Mazdutide is Metabolic · Incretin.
- Primary research focus: 5-Amino-1MQ — diet-induced obesity (rodent); Mazdutide — chronic weight management.
- Tag: Metabolic vs Weight loss.